A cheap buyout of IPIX could only happen if there were not multiple suitors interested in one or more of the three principal drugs, and based on what we know -- that we have more than 20 CDA'S in place, I don't see that happening. Leo has the most to lose and the most to gain, and my money is on him striking a lucrative deal with a global pharmaceutical company soon. A successful FDA meeting will be our turning point. We will have the funding necessary to move forward in developing all of the big three: B, P and K. All imo.